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Abstract
Background: Glucagon is a peptide hormone with many uses as a therapeutic agent, including the
emergency treatment of hypoglycemia. Physical instability of glucagon in solution leads to problems
with the manufacture, formulation, and delivery of this pharmaceutical product. Glucagon has been
shown to aggregate and form fibrils and gels in vitro. Small oligomeric precursors serve to initiate
and nucleate the aggregation process. In this study, these initial aggregates, or seed nuclei, are
characterized in bulk solution using light scattering methods and field-flow fractionation.
Results: High molecular weight aggregates of glucagon were detected in otherwise monomeric
solutions using light scattering techniques. These aggregates were detected upon initial mixing of
glucagon powder in dilute HCl and NaOH. In the pharmaceutically relevant case of acidic glucagon,
the removal of aggregates by filtration significantly slowed the aggregation process. Field-flow
fractionation was used to separate aggregates from monomeric glucagon and determine relative
mass. The molar mass of the large aggregates was shown to grow appreciably over time as the
glucagon solutions gelled.
Conclusion: The results of this study indicate that initial glucagon solutions are predominantly
monomeric, but contain small quantities of large aggregates. These results suggest that the initial
aggregates are seed nuclei, or intermediates which catalyze the aggregation process, even at low
concentrations.
Background
Glucagon is a 29-residue peptide hormone involved in the
regulation of blood glucose. Glucagon has several uses as
a therapeutic agent, including the emergency treatment of
hypoglycemia [1]. Pharmaceutical preparations of gluca-
gon are formulated in the amorphous solid state, and
must be solubilized immediately prior to administration.
Once in solution, glucagon is physically unstable and
must be discarded after 24 hours due to gel formation. In
dilute acid, the medium in which lyophilized glucagon is
normally solubilized, this gel formation has been shown
to result from the growth of fibrillar aggregates [2]. Pro-
tein aggregation is a problem in the manufacture, formu-
lation, and delivery of biopharmaceutical products like
glucagon. The presence of aggregates can result in reduced
biological activity, and other complications with
parenteral delivery, including increased immunogenicity
[3]. Understanding the aggregation process is important
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not only for the pharmaceutical production and therapeu-
tic use of glucagon, but also for elucidating a general
mechanism of fibril formation.
Much remains to be learned about the mechanism by
which proteins associate into amyloid fibrils, the charac-
teristic feature of over 20 degenerative conditions [4]. The
toxic species in such diseases has been identified as the
intermediates in the aggregation pathway rather than the
insoluble, mature fibrils and plaques [5,6], although the
exact molecular mechanism of pathogenesis is controver-
sial [7]. Protein aggregation has been described as a nucle-
ation-dependent process, specifically that the aggregation
rate can be seeded by the addition of intermediate aggre-
gates [8]. In general, determining the mechanism for fibril
formation at the molecular level may be the key to under-
standing the basis for amyloid toxicity and disease preven-
tion.
Glucagon has been presented as an ideal model for char-
acterizing fibril formation, since the aggregation process
can be studied at pharmaceutically and clinically relevant
conditions [9]. Recently, the structure of glucagon fibrils
has been probed extensively by atomic force microscopy
(AFM) [9-12] as well as electrophoretic and spectroscopic
techniques[13]. Various solution conditions have been
shown to result in at least two different types of mature
fibrils. However, the small oligomeric precursors which
serve to initiate and nucleate the process remain relatively
uncharacterized. In this study, these initial aggregates, or
seed nuclei, are characterized in bulk solution using light
scattering methods. The advantages of light scattering
techniques over other methods for studying fibril forma-
tion are that light scattering experiments are non-invasive
to the sample, and can provide absolute determination of
hydrodynamic size and molar mass. Unlike AFM, protein
aggregates are examined by light scattering in the bulk liq-
uid phase rather than as deposited or adsorbed species on
a solid substrate, where the growth and morphology of
aggregates may be quite different. Static and dynamic light
scattering have been used to monitor the aggregation
process of fibril-forming proteins such as β-amyloid
[14,15], α-synuclein [16], and huntingtin [17].
Traditionally, polydisperse protein solutions have been
separated by size-exclusion chromatography (SEC) for
downstream light scattering analysis. In a recent study, the
size of glucagon aggregates was evaluated by SEC [18].
However, viscous gel-like protein aggregates have been
known to cause plugging and fouling problems in chro-
matography columns, often leading to irreproducible
results. For this reason, the separation method of field-
flow fractionation (FFF) has been employed in this study.
This technology is unique in that it can be used to separate
materials over a much broader range of particle sizes than
traditional analytical methods, from 1 nm up to 100 μm.
Separation in FFF takes place in an open flow channel,
greatly reducing shear forces due to the absence of station-
ary phase. Asymmetric flow FFF can be coupled with
multi-angle laser light scattering for molar mass and size
determination independent of molecular weight stand-
ards. This combination of analytical methods has recently
been used to characterize polysaccharides [19], water-sol-
uble polymers [20], and nanosized drug carrier systems
[21,22]. However, it has not been widely used protein
applications. In this study, FFF is shown to be an effective
method for separating intermediate aggregates from mon-
omeric glucagon.
Static light scattering theory
In static light scattering (SLS) experiments, the time-aver-
aged intensity of scattered light is measured as a function
of particle concentration and scattering angle. These
measurements yield the weight-averaged molar mass
(Mw) of the scattering particles. If the size of the scattering
species is smaller than λ/20 it will behave as a point
source. In this case, a simplified form of the Debye equa-
tion, based on Rayleigh-Gans-Debye theory, can be
applied for vertically polarized light,
where
c is the concentration of the scattering species in solution,
Rθ is the Rayleigh ratio or the excess intensity of scattered
light at θ scattering angle, NA is Avogadro's number, λ is
the wavelength of the laser light source, n0 is the refractive
index of the solvent, and B22 is the second osmotic virial
coefficient of the scattering species.
The Mw is determined by plotting values of Kc/Rθ versus
particle concentration at a given scattering angle. This
graphical representation is referred to as a Debye plot. The
y-intercept determined through linear regression gives the
reciprocal weight-averaged molar mass (1/Mw) of particles
in solution.
Dynamic light scattering theory
Dynamic light scattering (DLS) measures fluctuations in
the intensity of scattered light which arise from thermal
motion of particles in the system. Analysis of these tempo-
ral fluctuations allows for estimation of the diffusion coef-
ficient, D, which can be used to determine the apparent
hydrodynamic radius (Rh) and particle size distribution
(PSD) of the scattering species. The rate at which the scat-
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tered light fluctuates is directly related to the "speed" at
which molecules move due to diffusion. The time auto-
correlation function of the scattered light intensity G2(t)
provides a quantitative measure of the particle motion.
Most theory is developed using the scattered electric field
autocorrelation function g1(t), which is easily calculated
from the experimentally measured light intensity autocor-
relation function by use the Siegert relationship,
where G2(∞) is the baseline of the experimentally meas-
ured intensity autocorrelation function.
For non-interacting, monodisperse particles that are small
compared with the wavelength of light, the scattered elec-
tric field correlation function g1(t) decays exponentially,
g1(t) = exp(-t/τ)( 4 )
where τ is the relaxation time of the scattered field corre-
lation function, and can be related to the diffusion coeffi-
cient of the scattering species
with scattering vector, q, given by
q = (4πn0/λ) sin (θ/2) (6)
The apparent Rh can be determined using the Stokes-Ein-
stein relationship, which relates the diffusion coefficient
of a hard sphere at infinite dilution (D0) to its hydrody-
namic radius
where k is the Boltzmann constant and η is the solvent vis-
cosity at absolute temperature, T. This simplified analysis
ignores concentrative effects due to hydrodynamic and
thermodynamic interactions which have been described
elsewhere.
Information about relaxation time and apparent hydrody-
namic radius distributions can be extracted from the data
by regressing appropriate theoretical models to the auto-
correlation function. For example, if a bimodal distribu-
tion is expected, a two-exponential fit is performed
estimate the two relaxation times independently.
g1(t) = a1 exp(-t/τ1) + a2 exp(-t/τ2)( 8 )
Parameters a1 and a2 are expansion coefficients known as
light intensity weighted amplitudes and τ1 and τ2 are relax-
ation times.
Generalizing from this approach to systems having multi-
ple particle sizes or broad size distributions is straightfor-
ward in principle, but requires specialized computational
approaches in practice. Each scattering species can be rep-
resented by a corresponding relaxation time, resulting in
a sum of exponentials
g1(t) = a1 exp(-t/τ1) + a2 exp(-t/τ2)+... (9)
where  an  values represent the relative contributions
(amplitudes) of each particle size. The regularized inverse
Laplace transform program CONTIN is routinely utilized
to perform such multi-exponential analyses of relaxation-
time distributions [23]. Under the assumption that the
scattering particles behave as hard spheres in dilute solu-
tion, the relaxation time distribution obtained can be con-
verted into an apparent hydrodynamic size distribution
using the Stokes-Einstein relationship.
FFF/MALS theory
The theory and principles of asymmetric flow FFF have
been extensively reviewed elsewhere [24-26]. In sum-
mary, this type of FFF is performed inside a thin, ribbon-
like channel approximately 30 cm in length, 2 cm wide,
and ranging in thickness up to 500 μm. Carrier fluid is
pumped through the channel from the inlet end exhibit-
ing a laminar flow profile. A cross-flow is induced perpen-
dicular to the channel flow, which exits the channel
through the bottom wall fitted with an ultrafiltration
membrane. The cross-flow forces the sample components
toward this "accumulation wall" of the channel, where a
concentration gradient is established. Small particles with
higher diffusion coefficients achieve equilibrium posi-
tions at higher levels in the channel than larger particles,
and are thus transported through the channel more rap-
idly due to the parabolic profile of the channel flow. Con-
sequently, small particles elute first, opposite the order of
elution in SEC.
In the manner described above, FFF accomplishes the sep-
aration of different sized particles in polydisperse solu-
tions for analysis by downstream detectors. Molar masses
of the fractionated species are determined using a multi-
angle light scattering (MALS) detector which collects on-
line SLS measurements at multiple scattering angles. The
linear Zimm method [27] is used to obtain molar mass by
setting  B22 to zero and extrapolating to zero scattering
angle.
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Methods
Preparation of Protein Standards for FFF/MALS Method 
Validation
The following protein standards were obtained in lyophi-
lized powder form from Sigma Aldrich (St. Louis, MO):
bovine serum albumin (BSA), alcohol dehydrogenase, β-
amylase, apoferritin, and thyroglobulin. All protein stand-
ards were dissolved in Dulbecco's phosphate buffer solu-
tion (PBS), pH 6.5, also obtained in powder form from
Sigma and dissolved in chromatography grade Optima
water from Fisher Scientific (Fair Lawn, NJ). PBS was fil-
tered with 0.1 μm filters before use.
Preparation of Glucagon Solutions
Lyophilized glucagon powder was donated by Eli Lilly
and Company (Indianapolis, IN). Solvents used were cer-
tified 0.01 N HCl or 0.01 N NaOH purchased from Fisher
Scientific (Fair Lawn, NJ). Prior to the addition of gluca-
gon, the small quantities of solvents used in these studies
were filtered through 0.02 μm syringe filters. This step is
necessary in order to produce dust-free diluents required
for light scattering studies. The glucagon powder was then
dissolved in the dust-free HCl or NaOH. Light scattering
experiments were performed on the glucagon solutions,
both before and after an additional filtration using either
0.1 or 0.2 μm solvent filters obtained from Millipore
(Bedford, MA) and Whatman (Kent, UK). A process dia-
gram detailing the solvent and glucagon solution prepara-
tions is shown in Figure 1. Glucagon concentrations were
determined spectrophotometrically using E (1 mg/mL; 1
cm) = 2.38 at 278 nm.
SLS and DLS measurements
SLS and DLS experiments were conducted with an ALV-
GmbH (Langen, Germany) SP-125 Compact DLS/SLS
Goniometer. The majority of experiments presented here
utilized a vertically polarized 400 mW diode-pumped,
solid-state Coherent DPSS532-400 laser (Coherent Inc.,
Santa Clara, CA) operating at 532 nm wavelength as the
light source. Glucagon solutions were prepared as previ-
ously described, placed in the sample compartment, fixed
to restrict movement, and equilibrated at 30°C by a ther-
mostatted bath. In DLS experiments, the apparent hydro-
dynamic size and PSD of glucagon samples were
determined by obtaining autocorrelation functions of the
scattered light intensity, G2(t), using an ALV-5000/E mul-
tiple tau digital correlator. Time correlation functions
were analyzed using CONTIN software to determine Rh
and PSD. The specific refractive index (dn/dc) of glucagon
was measured using a Bellingham & Stanley (Kent, UK)
60/ED Abbe refractometer with the laser light source
described. The values obtained for dn/dc at 532 nm were
0.175 in HCl and 0.189 in NaOH.
FFF/MALS
Asymmetric flow FFF experiments were carried out with
an Eclipse F separation system from Wyatt Technology
Corporation (WTC, Santa Barbara, CA). For protein stand-
ard analysis, 250 μm channel thickness and 10 kDa
MWCO membranes were used, also obtained from WTC.
Protein standards were prepared in PBS as previously
described, and this buffer was used as the mobile phase.
For glucagon experiments, 450 μm channel thickness and
Process diagram depicting preparation of solvents and gluca- gon solutions Figure 1
Process diagram depicting preparation of solvents 
and glucagon solutions.Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
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1 kDa MWCO ultrafiltration membranes were used,
obtained from WTC. Glucagon solutions were prepared in
certified 0.01 N HCl as previously described, and this sol-
vent was used as the mobile phase. In all experiments,
samples were injected into the FFF channel using a man-
ual Rheodyne (Rohnert Park, CA) injection port. Channel
flow was set at 1 mL/min, and cross-flow rates were con-
trolled using the Eclipse2 software, version 2.3 (WTC).
FFF experiments were coupled with MALS detection for
molar mass determination. The MALS detector used was
an 18-angle DAWN EOS (WTC), which employs a 685 nm
wavelength 30 mW linearly polarized Ga-As laser light
source. Molar mass calculations were made using ASTRA
software (WTC). On-line concentration measurements
were made with a Shimadzu (Columbia, MD) SPD-10AV
UV spectrophotometer set at a wavelength of 278 nm to
monitor the absorbance of light by glucagon.
Results and Discussion
Validation of FFF/MALS method for protein 
characterization
Separation of BSA oligomers was demonstrated using the
FFF/MALS method described, in order to validate this
method as suitable for protein separation. BSA is a com-
mon protein with a monomer molecular weight of 67
kDa that is known to form well defined oligomers in solu-
tion. This experiment is routinely used to optimize FFF
performance. Figure 2 shows an optimal BSA separation,
with 70 μg of BSA injected using PBS as mobile phase. The
relative light scattering intensity of BSA monomer, dimer,
trimer, tetramer and higher order aggregates can be iden-
tified.
In order to demonstrate the ability of FFF/MALS to not
only speciate aggregates, but also to provide absolute
molecular weight determination, a mixture of five differ-
ent protein standards was analyzed: BSA, alcohol dehy-
drogenase, β-amylase, apoferritin, and thyroglobulin. The
light scattering signal for the five separated proteins is
shown in Figure 3. The injected quantity of each protein is
shown in Table 1, along with a comparison between
expected molecular weights and the Mw inferred from the
light scattering results. The results of these FFF/MALS
experiments using protein standards demonstrate that FFF
is an effective method for separating proteins and protein
aggregates.
Presence of high molecular weight glucagon aggregates
Filtered glucagon solutions were analyzed immediately
after mixing by SLS to determine the weight-averaged
molar mass (Mw) using the Debye equation (Eqn. 1). The
excess Rayleigh ratio at 90° scattering angle, R90, was
measured over a range of known concentrations. By plot-
ting values of Kc/R90 over a range of concentrations, the
Mw was determined from the inverse of the y-intercept
value. Debye plots of Kc/R90 as a function of concentration
for acidic and alkaline glucagon solutions are shown in
Figure 4 and Figure 5. The Mw of soluble glucagon in the
acidic pH region was determined to be 3539 ± 372 g/mol.
Glucagon in alkaline solutions exhibited a slightly higher
Mw, 3831 ± 275 g/mol. This slightly higher alkaline Mw
Relative light scattering intensity vs. elution time for optimal separation of BSA oligomers by FFF/MALS Figure 2
Relative light scattering intensity vs. elution time for optimal separation of BSA oligomers by FFF/MALS.Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
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may indicate the presence of higher molecular weight
aggregates in the alkaline solutions. In order to verify this,
DLS was utilized to further probe these samples.
Relaxation time distributions before and after filtration
for both acidic and alkaline glucagon were obtained from
CONTIN analysis of light intensity autocorrelation func-
tions. The particle Rh distribution functions were calcu-
lated from the relaxation time distributions using the
Stokes-Einstein relationship. CONTIN analysis generated
Rh distribution plots of unfiltered acidic and alkaline glu-
cagon solutions are shown in Figure 6a and 6b. These
unfiltered glucagon solutions in dilute acid and base
showed bimodal Rh  distributions with peak Rh  values
around 1 and 100 nm, with the 1 nm peak indicating
monomeric glucagon. The monomeric radius of glucagon
can be confirmed using an accepted equation for approx-
imating the volume of a typical monomeric protein from
the Mw[28]. Using a literature reported molecular weight
of 3485 g/mol, which is based on the amino acid
sequence of glucagon, the estimated monomeric radius is
1.02 nm.
Removal of aggregates in acidic glucagon solutions slows 
gelation rate
DLS results indicate that acidic and alkaline glucagon
solutions exhibit distinctly different behavior following
filtration. Bimodal distributions were still present follow-
ing the filtration of alkaline glucagon solutions (Fig. 6c),
whereas the higher molecular weight aggregates were
eliminated by filtration of acidic glucagon solutions (Fig.
6d). The bimodal distribution that remained after filtra-
tion of alkaline glucagon solutions showed the larger sub-
population peak hydrodynamic radius value shifting to a
slightly smaller Rh of 61 nm from its original size of 100
nm.
These DLS results indicate the presence of higher molecu-
lar weight aggregates that can be removed by filtration
from acidic but not alkaline solutions. The filter retention
may be related to the relative charge of the filter mem-
brane or to the relative rigidity of the aggregates. Since the
filters used were designed to have low affinity for protein,
Separation of protein standards by FFF/MALS showing 90 degree light scattering signal vs. elution time Figure 3
Separation of protein standards by FFF/MALS showing 90 degree light scattering signal vs. elution time.
Table 1: Protein standards expected MW compared with Mw 
inferred from FFF/MALS experiments
Protein
Standard
Injected
amount 
(μg)
Expected
MW 
(kDa)
Mw inferred from
light scattering
(kDa)
BSA monomer 42.5 67 62.8
alcohol dehydrogenase 59.2 150 137.4
β-amylase 20.8 200 202.8
apoferritin 28.8 443 440.1
thyroglobulin 58.3 669 675.2Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
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the aggregate rigidity seems to be the more plausible
explanation for the observed effects.
The effect of pre-existing aggregates on aggregation rate
was further investigated by measuring the raw light scat-
tering signal intensity of freshly prepared 4 mg/mL gluca-
gon solutions in 0.01 N HCl over a period of three days
(Fig. 7). The rapid increase in light scattering intensity for
the unfiltered glucagon preparation suggests that the pres-
ence of initial aggregates serve to nucleate the aggregation
process. Conversely, the filtered acid glucagon prepara-
tion with the absence of initial aggregates stayed stable in
solution for 50 hours.
Characterization of glucagon aggregates by FFF/MALS
To further quantify the two subpopulations within the
unfiltered samples, SEC experiments were attempted. SEC
proved ineffective in monitoring the molecular weight
distribution of aggregating glucagon systems (data not
shown). Aggregates present in glucagon solutions injected
Debye plot of glucagon immediately upon dissolving in 0.01 N HCl Figure 4
Debye plot of glucagon immediately upon dissolving in 0.01 N HCl. Measurements obtained by static light scattering 
at 30°C and a 90° scattering angle. Linear regression model generated using Kc/R90 and glucagon concentration yielded a y-
intercept of 2.8 (± 0.3) × 10-4, which corresponds to a Mw = 3539 (± 372).
Debye plot of glucagon immediately upon dissolving in 0.01 N NaOH Figure 5
Debye plot of glucagon immediately upon dissolving in 0.01 N NaOH. Measurements obtained by static light scatter-
ing at 30°C and a 90° scattering angle. Linear regression model generated using Kc/R90 and glucagon concentration yielded a y-
intercept of 2.6 (± 0.2) × 10-4, which corresponds to a Mw = 3831 (± 275).Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
Page 8 of 11
(page number not for citation purposes)
into a column using 0.01 N HCl eluent caused fouling
and backpressure problems in the SEC system, and tended
to dissociate inside the column, emerging in the mono-
meric state. Thus, this method was abandoned as a means
to monitor the aggregation process.
FFF/MALS experiments were performed to verify the pres-
ence of large initial aggregates upon initial mixing of glu-
cagon in 0.01 N HCl, and to confirm that the large
aggregates can be removed by filtration, as previously
indicated by DLS results. The 100 nm aggregate popula-
tion was not concentrated enough to be detectable at the
low concentrations and small injection volumes typically
used with chromatographic methods. Therefore 250 μL of
a 14 mg/ml glucagon solution was injected into the FFF
channel for these experiments both before and after filtra-
tion with a 0.1 μm filter. Elution of a large aggregate peak
can be observed in the unfiltered sample, but not in the
filtered sample (Fig. 8). The use of a UV detector down-
stream of the FFF unit allowed for the verification that the
large particles are indeed protein, since this peak exhibits
measurable UV absorbance at 278 nm.
A high concentration unfiltered glucagon solution in 0.01
N HCl was again analyzed by FFF, both before and after
22 hours of incubation at 22°C. Initially, weight averaged
molar mass of the monomer was analyzed by MALS to be
3650 g/mol, with a large aggregate peak of 1.2 × 105 g/
mol. After the incubation period, the sample was
observed to be partially gelled. When this sample was
again analyzed by FFF/MALS, the molar mass of the large
aggregate had increased significantly to 1.9 × 106 g/mol.
The histograms in Figure 9 show the relative molar mass
distributions for the two cases. The large aggregates are on
the order of 1% of total injected mass, but the molar mass
distributions for these peaks cannot be further analyzed
due to extremely low UV signal strength.
Conclusion
These results indicate that initial glucagon solutions are
predominantly monomeric, but contain small quantities
of large aggregates. Although the concentration of these
initial aggregates is low, these particles serve to catalyze or
nucleate new aggregates. Separating and characterizing
the large particles which absorb UV at 278 nm by FFF sug-
gests that these particles are aggregates of glucagon that
grow over time. Thus, further aggregation of glucagon is
accelerated by these seed nuclei, by a process such as
where nM represents n glucagon monomers, and Mn rep-
resents an oligomeric species of number n. It was demon-
strated that filtration can remove the large aggregates in
some situations.
These findings describe an important aspect of the aggre-
gation behavior of glucagon, which is considered a model
amyloidgenic protein. This work contributes to the field
of biological engineering because of its relevance to drug
formulation and delivery, as well as clinical applications.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CH carried out SLS, DLS, and FFF experiments. LN carried
out SLS and DLS experiments. CH, JW, and LN all contrib-
uted to the writing of the manuscript. JW and LK con-
ceived of the study, and participated in its design and
coordination. All authors read and approved the final
manuscript.
nM M
catalyzedby M
n
n ⎯→ ⎯⎯⎯⎯⎯ ⎯ (10)
Hydrodynamic size distributions obtained from relaxation  time distributions corresponding to the autocorrelation func- tions of unfiltered and filtered glucagon solutions Figure 6
Hydrodynamic size distributions obtained from 
relaxation time distributions corresponding to the 
autocorrelation functions of unfiltered and filtered 
glucagon solutions. (a) and (b) represent the PSD of unfil-
tered glucagon in 0.01 N NaOH and HCl, respectively, (c) 
and (d) represents 0.2 μm filtered alkaline and acid glucagon 
solutions, respectively.Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
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Raw scattered light intensity from ALV SLS detector vs. time for filtered and unfiltered glucagon preparations in dilute HCl Figure 7
Raw scattered light intensity from ALV SLS detector vs. time for filtered and unfiltered glucagon preparations 
in dilute HCl.
Relative intensity of Rayleigh ratio from MALS detector for filtered and unfiltered glucagon solutions in 0.01 N HCl Figure 8
Relative intensity of Rayleigh ratio from MALS detector for filtered and unfiltered glucagon solutions in 0.01 N 
HCl. Monomer and aggregates have been separated by asymmetric flow FFF in the unfiltered sample. Aggregates have been 
removed from the solution in the filtered sample.Journal of Biological Engineering 2008, 2:10 http://www.jbioleng.org/content/2/1/10
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